Media Overview | Boehringer Ingelheim CA
Media overview
Explore our latest news releases and media information.
News releases
[The hidden impact of veterinary care: new insights from a global survey of veterinarians](/content/ca/hidden-impact-veterinary-care "The hidden impact of veterinary care"/index.html)
June 23, 2026
The hidden impact of veterinary care: new insights from a global survey of veterinarians
[Read more](/content/ca/hidden-impact-veterinary-care "Read more about "The hidden impact of veterinary care: new insights from a global survey of veterinarians""/index.html)
[Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity](/content/ca/press-release-0 "Press release"/index.html)
June 07, 2026
Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity
[Read more](/content/ca/press-release-0 "Read more about "Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity""/index.html)
[Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial](/content/ca/press-release "Press release"/index.html)
April 29, 2026
Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial
[Read more](/content/ca/press-release "Read more about "Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial""/index.html)
Media contacts
Sara McClelland
Communications, Media & Public Relations
Director, Communications
Phone (905) 631-4713
Mobile (905) 599-2364
Merry Garbutt
Communications, Media & Public Relations
Corporate Communications
Phone (905) 631-4531
Mobile (647) 637-8265
Anne Coffey
Specialist, Brand Communications
Phone (416) 526-5388
Pilar Iglesias
Healthcare Affairs Communications Manager
Phone: (647) 271-4717
News material
Access our media pool.
[Read more](/content/ca/new-material "Read more"/index.html)